Sodium-Glucose Cotransporter Inhibitors As Antidiabetic Drugs: Current Development and Future Perspectives

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2022 Aug 4

PMID 35924548

Authors

Rosanna Maccari

Rosaria Ottana

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (gliflozins) represent the most recently approved class of oral antidiabetic drugs. SGLT-2 overexpression in diabetic patients contributes significantly to hyperglycemia and related complications. Therefore, SGLT-2 became a highly interesting therapeutic target, culminating in the approval for clinical use of dapagliflozin and analogues in the past decade. Gliflozins improve glycemic control through a novel insulin-independent mechanism of action and, moreover, exhibit significant cardiorenal protective effects in both diabetic and nondiabetic subjects. Therefore, gliflozins have received increasing attention, prompting extensive structure-activity relationship studies and optimization approaches. The discovery that intestinal SGLT-1 inhibition can provide a novel opportunity to control hyperglycemia, through a multifactorial mechanism, recently encouraged the design of low adsorbable inhibitors selectively directed to the intestinal SGLT-1 subtype as well as of dual SGLT-1/SGLT-2 inhibitors, representing a compelling strategy to identify new antidiabetic drug candidates.

Citing Articles

Standardized Chromatographic and Computational Approaches for Lipophilicity Analysis of Five Gliflozin Antidiabetic Drugs in Relation to Their Biological Activity.

Gumieniczek A, Berecka-Rycerz A, Dul M, Pryjda A Molecules. 2025; 30(1.

PMID: 39795172 PMC: 11721022. DOI: 10.3390/molecules30010115.

Creating glycoside diversity through stereoselective carboboration of glycals.

Shen Z, Yu Y, Wu D, Wei Z, Kong W, Li Y Nat Commun. 2024; 15(1):10167.

PMID: 39580431 PMC: 11585543. DOI: 10.1038/s41467-024-54016-4.

The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients.

Sheu J, Chang L, Chen J, Pan H, Tseng C, Chueh J Nat Commun. 2024; 15(1):10043.

PMID: 39567483 PMC: 11579355. DOI: 10.1038/s41467-024-54171-8.

Sodium-glucose cotransporter 1 promotes the biofunctions of perivascular preadipocytes mediated by Akt/mTOR/p70S6K signaling pathway.

Liu Z, Wang J, Tian P, Liu Y, Xing L, Fu C Am J Physiol Cell Physiol. 2024; 326(6):C1611-C1624.

PMID: 38646789 PMC: 11371362. DOI: 10.1152/ajpcell.00606.2023.

SGLT-2 inhibitors as novel treatments of multiple organ fibrosis.

Hu J, Teng J, Hui S, Liang L Heliyon. 2024; 10(8):e29486.

PMID: 38644817 PMC: 11031788. DOI: 10.1016/j.heliyon.2024.e29486.

References

Muller M, Pruijm M, Bonny O, Burnier M, Zanchi A . Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol. Adv Ther. 2018; 35(6):875-885. PMC: 6015115. DOI: 10.1007/s12325-018-0708-y. View

Kang S, Kim M, Lee J, Lee J . Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors. Bioorg Med Chem Lett. 2011; 21(12):3759-63. DOI: 10.1016/j.bmcl.2011.04.063. View

Hussey E, Clark R, Amin D, Kipnes M, OConnor-Semmes R, ODriscoll E . Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010; 50(6):623-35. DOI: 10.1177/0091270009351879. View

Hediger M, Coady M, IKEDA T, Wright E . Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987; 330(6146):379-81. DOI: 10.1038/330379a0. View

Powell D, Smith M, Greer J, Harris A, Zhao S, DaCosta C . LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013; 345(2):250-9. DOI: 10.1124/jpet.113.203364. View

Ehrenkranz J, Lewis N, Kahn C, Roth J . Phlorizin: a review. Diabetes Metab Res Rev. 2004; 21(1):31-8. DOI: 10.1002/dmrr.532. View

Rossetti L, Smith D, Shulman G, Papachristou D, DeFronzo R . Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79(5):1510-5. PMC: 424427. DOI: 10.1172/JCI112981. View

Imamura M, Nakanishi K, Suzuki T, Ikegai K, Shiraki R, Ogiyama T . Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012; 20(10):3263-79. DOI: 10.1016/j.bmc.2012.03.051. View

Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y . (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010; 53(8):3247-61. DOI: 10.1021/jm901893x. View

10.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y . Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2006; 320(1):323-30. DOI: 10.1124/jpet.106.110296. View

11.

Rahmoune H, Thompson P, Ward J, Smith C, Hong G, Brown J . Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005; 54(12):3427-34. DOI: 10.2337/diabetes.54.12.3427. View

12.

Lin J, Lorenz M, Fritz S, Kinne R . Probing the conformation of the sugar transport inhibitor phlorizin by 2D-NMR, molecular dynamics studies, and pharmacophore analysis. J Med Chem. 2000; 43(9):1692-8. DOI: 10.1021/jm9905460. View

13.

Kim M, Lee J, Kang S, Lee S, Son E, Jung M . Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners. Bioorg Med Chem Lett. 2010; 20(11):3420-5. DOI: 10.1016/j.bmcl.2010.04.006. View

14.

Giorgino F, Vora J, Fenici P, Solini A . Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes Obes Metab. 2020; 22(9):1481-1495. PMC: 7496739. DOI: 10.1111/dom.14055. View

15.

Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D . Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2011; 61(1):187-96. PMC: 3237647. DOI: 10.2337/db11-1029. View

16.

Bauer A, Bronstrup M . Industrial natural product chemistry for drug discovery and development. Nat Prod Rep. 2013; 31(1):35-60. DOI: 10.1039/c3np70058e. View

17.

Brito D, Bettencourt P, Carvalho D, Ferreira J, Fontes-Carvalho R, Franco F . Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. Cardiovasc Drugs Ther. 2020; 34(3):419-436. PMC: 7242490. DOI: 10.1007/s10557-020-06973-3. View

18.

Watanabe A, Choe S, Chaptal V, Rosenberg J, Wright E, Grabe M . The mechanism of sodium and substrate release from the binding pocket of vSGLT. Nature. 2010; 468(7326):988-91. PMC: 3736980. DOI: 10.1038/nature09580. View

19.

Barnett A, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H . Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 2(5):369-84. DOI: 10.1016/S2213-8587(13)70208-0. View

20.

Wilcox C . Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020; 75(4):894-901. DOI: 10.1161/HYPERTENSIONAHA.119.11684. View